329 related articles for article (PubMed ID: 12426858)
1. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
5. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
7. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms].
Wirth MP; Helke C; Froschermaier SE
Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
9. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
10. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
11. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
Rabasseda X
Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
[TBL] [Abstract][Full Text] [Related]
12. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
13. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
14. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
15. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
16. 5 alpha-reductase inhibitors: what's new?
Foley CL; Kirby RS
Curr Opin Urol; 2003 Jan; 13(1):31-7. PubMed ID: 12490813
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Djavan B; Milani S; Fong YK
Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
[TBL] [Abstract][Full Text] [Related]
18. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
[No Abstract] [Full Text] [Related]
19. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
[TBL] [Abstract][Full Text] [Related]
20. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
